|Description||Early Diagnosis of Alzheimer's|
|Seed, 5/2013 ||$90k|
|Series A, 9/2013 |
The Social+Capital Partnership
Neurotrack’s technology can diagnose Alzheimer’s Disease up to six years before symptoms occur. Based on ground-breaking research, it enables pharmaceutical companies and researchers to recruit qualified candidates for clinical trials, and more effectively measure drug efficacy, speeding up drug discovery and development.
Neurotrack is also becoming the standard for early clinical screening of Alzheimer’s and dementia related disorders.